Biorestorative Therapies (NASDAQ:BRTX) Shares Down 2.7% – Here’s Why

Biorestorative Therapies, Inc. (NASDAQ:BRTX)’s share price was down 2.7% during mid-day trading on Monday . The company traded as low as $1.0550 and last traded at $1.08. Approximately 26,495 shares were traded during trading, a decline of 67% from the average daily volume of 80,172 shares. The stock had previously closed at $1.11.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, December 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Biorestorative Therapies Stock Performance

The firm has a market cap of $9.59 million, a P/E ratio of -0.73 and a beta of 0.18. The firm’s fifty day moving average is $1.39 and its 200 day moving average is $1.53.

Biorestorative Therapies (NASDAQ:BRTX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 231.08%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.46 million. As a group, equities research analysts forecast that Biorestorative Therapies, Inc. will post -1.43 EPS for the current year.

Institutional Trading of Biorestorative Therapies

A hedge fund recently raised its stake in Biorestorative Therapies stock. Virtu Financial LLC raised its position in Biorestorative Therapies, Inc. (NASDAQ:BRTX) by 102.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,351 shares of the company’s stock after buying an additional 12,319 shares during the quarter. Virtu Financial LLC owned 0.31% of Biorestorative Therapies worth $35,000 at the end of the most recent reporting period. Institutional investors own 69.38% of the company’s stock.

About Biorestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.